Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  L. See,et al.  Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan , 2020, JAMA network open.

[3]  J. Herrmann.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia , 2020, Nature Reviews Cardiology.

[4]  Wen-Chung Lee,et al.  Taiwan's Nationwide Cancer Registry System of 40 years: Past, present, and future. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[5]  J. Moslehi,et al.  Cardiovascular Toxic Effects of Targeted Cancer Therapies. , 2016, The New England journal of medicine.

[6]  D. Steensma,et al.  Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. , 2015, Journal of the American College of Cardiology.

[7]  M. Lai,et al.  Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[8]  Yang Yao,et al.  Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. , 2014, Critical reviews in oncology/hematology.

[9]  B. D. da Costa,et al.  Tools & techniques--statistics: propensity score techniques. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  Ching-Lan Cheng,et al.  Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan , 2014, Journal of epidemiology.

[11]  P. Austin.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[12]  J. B. Layton,et al.  Propensity Score Methods for Confounding Control in Nonexperimental Research , 2013, Circulation. Cardiovascular quality and outcomes.

[13]  Lane F Burgette,et al.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.

[14]  S. Srinivas,et al.  The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. , 2013, JACC. Heart failure.

[15]  T. Choueiri,et al.  Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Brian K. Lee,et al.  Weight Trimming and Propensity Score Weighting , 2011, PloS one.

[17]  T. Choueiri,et al.  Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Mohit Bhandari,et al.  How to work with a subgroup analysis. , 2009, Canadian journal of surgery. Journal canadien de chirurgie.

[20]  S. Cole,et al.  Competing risk regression models for epidemiologic data. , 2009, American journal of epidemiology.

[21]  M. Raebel,et al.  Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[23]  K. Stergiopoulos,et al.  Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis , 2009, Acta oncologica.

[24]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[25]  A. Kudelka,et al.  Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.

[26]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[27]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[28]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[29]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[30]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .

[31]  L. Minasian,et al.  Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma , 2016, Cancer.

[32]  J. Dalton,et al.  A unified approach to measuring the effect size between two groups using SAS , 2012 .